Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Financing

Akebia secures up to $140M Symbiotic Capital term loan, repays $55M BlackRock facility

Akebia Therapeutics announced a senior secured term loan with Symbiotic Capital, closed November 12, 2026 and disclosed November 16, 2026. A $60 million initial tranche was funded and used to repay its $55 million BlackRock loan in full, and up to $80 million more may be provided at the lender's discretion. The loan matures in 60 months at a variable rate of at least 11.5%, and the company reaffirmed cash runway guidance of at least two years.

16 Nov 2026 · Akebia Therapeutics, Inc. AKBA · Company news

Company's press release (SEC filing): Akebia Therapeutics, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →